Efineptakin alfa
Modify Date: 2024-01-11 19:54:07
Efineptakin alfa structure
|
Common Name | Efineptakin alfa | ||
|---|---|---|---|---|
| CAS Number | 2026634-47-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Efineptakin alfaEfineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4+ and CD8+ cells in both human and mice. Efineptakin alfa can be used for glioblastoma research[1]. |
| Name | Efineptakin alfa |
|---|
| Description | Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4+ and CD8+ cells in both human and mice. Efineptakin alfa can be used for glioblastoma research[1]. |
|---|---|
| Related Catalog | |
| Target |
IL7R |
| In Vivo | Efineptakin alfa (10mg /kg，肌肉注射，单次) 联合 SLC-3010 (1.8 mg/kg，静脉注射，单次)抑制 MC38 荷瘤小鼠的肿瘤生长[2]。 Efineptakin alfa (10 mg/kg) 在原位胶质瘤荷瘤小鼠中，可减轻放疗相关的淋巴细胞减少，增加全身和肿瘤中的细胞毒性 CD8 T 淋巴细胞，并提高原位胶质瘤荷瘤小鼠的存活率[1]。 Animal Model: C57BL/6 mice bearing intracranial tumors (GL261 or CT2A)[1] Dosage: 10 mg/kg Administration: On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion Result: Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFNγ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow. |
| References |
| No Any Chemical & Physical Properties |